This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A second examination of the clinical landscape of renal disease and the potential of anticoagulant therapies in this space for the prevention of cardiovascular events, including Merck's MK-2060.
Ticker(s): MRKWho's the expert?
Institution: Stormont-Vail Health
- Nephrologist who sees 400 end stage renal disease patients, 150 which are on dialysis
- Division director of Nephrology and Stormont-Vail Health
- Medical director DaVita, University of Kansas Topeka Campus
Interview GoalInterview a nephrologist to better understand the treatment of renal disease patients. Also taking a close look at the potential of Merck's anticoagulation therapy, MK-2060, which has just received FDA fast track designation for the treatment of ESRD patients undergoing hemodialysis.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
